Clinical trial

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

NCT04176081

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Darolutamide Normalized identity: darolutamideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Degarelix Normalized identity: degarelixView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiation Therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-07-02

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

DarolutamideDRUG · verified · RxNorm: darolutamide

DegarelixDRUG · verified · RxNorm: degarelix

Radiation TherapyRADIATION

Sponsors & collaborators

University Health Network, Torontolead sponsor

Prostate Cancer Canadacollaborator

Bayercollaborator

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04176081 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.